News 05.09.2025 AL-S Pharma today announced positive topline results from the Phase 2 clinical study evaluating AP-101, a potential first-in-class, disease-modifying treatment for amyotrophic lateral sclerosis (ALS). AP-101 is a monoclonal antibody targeting misfolded SOD1, a key pathology in both sporadic ALS and mutant SOD1-ALS.1 AP-101, in addition to standard of care, met...
News 26.08.2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced corporate...
News 21.08.2025 Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing...
News 20.08.2025 Schlieren / Zurich, Switzerland, 19 August, 2025 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, has published Phase I clinical data in Clinical and Translational Science, highlighting the safety, tolerability, and pharmacokinetics (PK) of its lead clinical asset, potravitug,...
News 14.08.2025 Schlieren (Zurich), Switzerland, August 14, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced its financial and operational results for the first half of 2025, demonstrating continued momentum in growth, broader market reach, and progress on key strategic priorities. Total group revenue...